TY - JOUR
T1 - Hemodynamic improvement after oral hydralazine in left ventricular failure. A comparison with nitroprusside infusion in 16 patients
AU - Franciosa, J. A.
AU - Pierpont, G.
AU - Cohn, Jay N
PY - 1977/1/1
Y1 - 1977/1/1
N2 - Hydralazine was administered in a single oral dose of 50 to 100 mg in 16 patients with left ventricular failure due to cardiomyopathy. It produced sustained effects for at least 4 h characterized by a significant increase in cardiac output, a reduction in arterial and pulmonary arterial pressure, and a slight rise in heart rate. When compared to nitroprusside infusion in these same patients, hydralazine produced a similar reduction in systemic vascular resistance but a slightly greater increase in cardiac index (0.74 versus 0.95 litres/min.m2), with a lesser fall in mean arterial pressure (7.8 versus 13.6 mm Hg, P<0.01), mean pulmonary arterial pressure (4.2 versus 11.3 mm Hg, P<0.001), and pulmonary wedge pressure (5.5 versus 9.9 mm Hg, P<0.001). Forearm venous tone decreased and venous compliance increased during nitroprusside infusion, but they were unchanged after hydralazine therapy. These data suggest that hydralazine may be a useful agent in the treatment of chronic left ventricular failure.
AB - Hydralazine was administered in a single oral dose of 50 to 100 mg in 16 patients with left ventricular failure due to cardiomyopathy. It produced sustained effects for at least 4 h characterized by a significant increase in cardiac output, a reduction in arterial and pulmonary arterial pressure, and a slight rise in heart rate. When compared to nitroprusside infusion in these same patients, hydralazine produced a similar reduction in systemic vascular resistance but a slightly greater increase in cardiac index (0.74 versus 0.95 litres/min.m2), with a lesser fall in mean arterial pressure (7.8 versus 13.6 mm Hg, P<0.01), mean pulmonary arterial pressure (4.2 versus 11.3 mm Hg, P<0.001), and pulmonary wedge pressure (5.5 versus 9.9 mm Hg, P<0.001). Forearm venous tone decreased and venous compliance increased during nitroprusside infusion, but they were unchanged after hydralazine therapy. These data suggest that hydralazine may be a useful agent in the treatment of chronic left ventricular failure.
UR - http://www.scopus.com/inward/record.url?scp=0017344496&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0017344496&partnerID=8YFLogxK
U2 - 10.7326/0003-4819-86-4-388
DO - 10.7326/0003-4819-86-4-388
M3 - Article
C2 - 848799
AN - SCOPUS:0017344496
VL - 86
SP - 388
EP - 393
JO - Annals of Internal Medicine
JF - Annals of Internal Medicine
SN - 0003-4819
IS - 4
ER -